greeksoup/ stock research

Mimedx Group (MDXG) Q4 FY2023 earnings: revenue $87 million, up 16.7% on the year

Mimedx Group, Inc. (MDXG) reported revenue of $87 million for Q4 FY2023, the quarter ended 31 December 2023, up 16.7% on the same quarter a year earlier. Net income was $53 million. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2024.

Revenue$87 millionup 16.7%
Net income$53 million
Diluted EPSn/a
QuarterQ4 FY2023ended 31 December 2023

The quarter, against the one before and a year earlier

LineQ4 FY2023Q3 FY2023Q4 FY2022Change on the year
Revenue86.881.774.4+16.7%
Cost of revenue13.814.814.4-3.7%
Gross profit73.066.960.0+21.6%
Gross margin84.1%81.9%80.7%
Research and development2.43.15.4-54.9%
Selling, general and administrative54.352.650.0+8.8%
Operating income15.511.11.1+1350.7%
Operating margin17.8%13.6%1.4%
Pre-tax income13.99.4-0.4n/a
Income tax-37.40.60.0n/a
Effective tax rate-268.6%6.3%n/a
Net income53.58.5-0.4n/a
Net margin61.6%10.4%-0.6%
Diluted EPSn/a$0.06-$0.02n/a
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

LineQ4 FY2023Q3 FY2023Q4 FY2022Change on the year
Operating cash flow10.312.8-5.6n/a
Capital expenditure0.40.60.7-36.0%
Free cash flow9.812.2-6.3n/a
Free cash flow margin11.3%14.9%-8.5%
Cash from investing-0.5-0.6-1.7n/a
Cash from financing-8.90.40.1n/a
Depreciation and amortisation0.80.81.0-17.9%
Share-based compensation4.24.41.9+123.0%
Diluted shares, weighted146m119m113m+29.3%
Shares outstanding at period end146m116m114m+28.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2023Q3 FY2023Q4 FY2022Change on the year
Shareholders' equity1431.3-18.0n/a
Redeemable equity0.092.592.5n/a
Debt50.049.050.0+0.0%
Operating lease liabilities0.9n/a2.4-62.5%
Finance lease liabilities0.0n/a0.1-91.2%
Other liabilities45.446.244.5+2.1%
Total liabilities and equity239189171+39.4%
Goodwill19.419.420.0-2.7%
Intangible assets5.35.45.9-10.2%
Cash and equivalents82.081.266.0+24.3%
Receivables53.949.043.1+25.0%
Inventory21.019.113.2+59.5%
Other assets57.514.923.4+145.7%
Total assets239189171+39.4%

Questions

What was Mimedx Group's revenue in Q4 FY2023?

Mimedx Group (MDXG) reported revenue of $87 million for Q4 FY2023, the quarter ended 31 December 2023, up 16.7% on the same quarter a year earlier.

How much did Mimedx Group earn in Q4 FY2023?

Net income for Q4 FY2023 was $53 million.

When did Mimedx Group report Q4 FY2023 results?

Mimedx Group filed its 10-K for the year that ended with the quarter on 28 February 2024; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 * †Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue67.458.966.967.774.471.781.381.786.884.787.284.192.988.298.611411859.064.462.3
Cost of revenue10.89.911.812.214.412.413.614.813.813.014.915.316.916.618.718.719.117.420.012.6
Gross profit56.749.055.155.560.059.367.766.973.071.772.468.776.071.679.995.099.041.644.449.7
Gross margin84%83%82%82%81%83%83%82%84%85%83%82%82%81%81%84%84%71%69%80%
R&D4.66.05.56.05.43.53.73.12.42.83.02.93.63.33.33.74.84.12.82.8
SG&A53.149.655.853.550.052.351.952.654.355.155.453.561.060.064.269.073.153.259.858.3
Operating income3.3-9.3-9.6-7.11.1-0.310.811.115.513.223.411.211.18.312.422.221.1-16.0-18.5-11.7
Operating margin5%-16%-14%-10%1%-0%13%14%18%16%27%13%12%9%13%20%18%-27%-29%-19%
Interest expensen/an/an/an/an/an/an/an/an/a2.40.50.50.50.50.50.40.40.4n/an/a
Pre-tax income2.1-10.4-10.8-8.4-0.4-1.99.29.413.911.423.211.411.28.613.022.821.8-15.3-17.8-11.1
Tax rate-5%n/an/an/an/an/a-1%6%-269%21%24%31%34%18%26%27%30%n/an/an/a
Net income2.2-10.5-10.9-8.4-0.4-5.01.28.553.59.317.68.17.47.09.616.715.2-10.9-14.8-8.7
Net margin3%-18%-16%-12%-1%-7%1%10%62%11%20%10%8%8%10%15%13%-18%-23%-14%
Diluted EPS$0.01-$0.11-$0.11-$0.09-$0.02-$0.06$0.00$0.06n/a$0.06$0.12$0.05$0.05$0.05$0.06$0.11$0.10-$0.07-$0.10-$0.06
Operating cash flow-3.2-10.2-3.01.0-5.6-4.07.812.810.36.021.819.618.85.314.429.325.01.9-10.03.9
Capital expenditure0.30.10.40.30.70.60.30.60.41.10.10.20.30.40.20.20.30.60.60.2
Free cash flow-3.6-10.3-3.40.6-6.3-4.77.512.29.84.821.719.518.54.914.229.124.71.3-10.63.8
Buybacksn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a0.0n/an/an/a0.3
Shares outstanding112m113m114m114m114m115m116m116m146m148m147m147m147m148m148m148m148m149m146m146m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2023, filed 28 February 2024: the filing.